PMID- 23744100
OWN - NLM
STAT- MEDLINE
DCOM- 20140715
LR  - 20211021
IS  - 1432-1971 (Electronic)
IS  - 0172-0643 (Linking)
VI  - 34
IP  - 8
DP  - 2013
TI  - N-terminal pro-brain natriuretic peptide (NT proBNP) as a predictive indicator of 
      initial intravenous immunoglobulin treatment failure in children with Kawasaki 
      disease: a retrospective study.
PG  - 1837-43
LID - 10.1007/s00246-013-0724-2 [doi]
AB  - Intravenous immunoglobulin (IVIG) administered in the acute stage of Kawasaki 
      disease (KD) is the standard therapy. Few reports describe nonresponders to 
      initial treatment with IVIG in KD, which remains the most consistent risk factor 
      for coronary artery lesions (CALs). This study aimed to investigate whether the 
      serum level of N-terminal pro-brain natriuretic peptide (NT-proBNP) can be a 
      predictive indicator for identifying patients with KD at higher risk of IVIG 
      treatment failure. In this study, 135 patients with a diagnosis of KD admitted 
      for IVIG treatment were retrospectively enrolled for analysis. Of these 135 
      patients, 22 were nonresponders who received additional rescue therapy because 
      they had an elevated body temperature 36 h after completion of initial IVIG 
      treatment. The NT-proBNP concentration was significantly higher in the 
      nonresponder group (2,465.36 +/- 3,293.24 pg/mL) than in the responder group 
      (942.38 +/- 1,293.48 pg/mL) (p < 0.05). The optimal sensitivity and specificity 
      cutoff point for predicted nonresponders was 1,093.00 pg/mL or higher. The 
      sensitivity and specificity for prediction of IVIG response were respectively 
      70.0 and 76.5 %. The findings show that NT-proBNP is a helpful marker in 
      determining patients at risk for not responding to initial IVIG treatment. The 
      authors suggest that patients with an NT-proBNP level of 1,093.00 pg/dL or higher 
      are likely to fail initial IVIG and may require further rescue therapy.
FAU - Kim, So Youn
AU  - Kim SY
AD  - Department of Pediatrics, Kyunghee University School of Medicine, 26 
      Kyungheedae-ro, Dongdaemun-gu, Seoul, 130-701, South Korea.
FAU - Han, Mi Young
AU  - Han MY
FAU - Cha, Sung-Ho
AU  - Cha SH
FAU - Jeon, Yang Bin
AU  - Jeon YB
LA  - eng
PT  - Journal Article
DEP - 20130607
PL  - United States
TA  - Pediatr Cardiol
JT  - Pediatric cardiology
JID - 8003849
RN  - 0 (Biomarkers)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
EIN - Pediatr Cardiol. 2014 Jan;35(1):189
MH  - Biomarkers/blood
MH  - Child, Preschool
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunoglobulins, Intravenous/*administration & dosage
MH  - Immunologic Factors/administration & dosage
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*blood/*drug therapy
MH  - Natriuretic Peptide, Brain
MH  - Peptide Fragments
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Treatment Failure
EDAT- 2013/06/08 06:00
MHDA- 2014/07/16 06:00
CRDT- 2013/06/08 06:00
PHST- 2013/03/04 00:00 [received]
PHST- 2013/05/20 00:00 [accepted]
PHST- 2013/06/08 06:00 [entrez]
PHST- 2013/06/08 06:00 [pubmed]
PHST- 2014/07/16 06:00 [medline]
AID - 10.1007/s00246-013-0724-2 [doi]
PST - ppublish
SO  - Pediatr Cardiol. 2013;34(8):1837-43. doi: 10.1007/s00246-013-0724-2. Epub 2013 
      Jun 7.